China Bioligic Products Holdings Inc (CBPO)

$CBPO Daily and Weekly Charts

$CBPO Daily Chart

$CBPO recent news/filings

bullish 128.81
bull flag breakout
shorts realizing it isn't a double top and covering

## source: finance.yahoo.com

Tue, 08 Dec 2015 18:17:01 GMT ~ CHINA BIOLOGIC PRODUCTS, INC. Financials


read full: http://finance.yahoo.com/q/is?s=cbpo
*********************************************************

Fri, 04 Dec 2015 14:25:28 GMT ~ Is Heartland Payment Systems, Inc. (HPY) Going to Burn These Hedge Funds?


read full: http://www.insidermonkey.com/blog/is-heartland-payment-systems-inc-hpy-going-to-burn-these-hedge-funds-394388/
*********************************************************

Mon, 23 Nov 2015 15:41:27 GMT ~ Is China Biologic Products Inc (CBPO) A Good Stock To Buy?


read full: http://www.insidermonkey.com/blog/is-china-biologic-products-inc-cbpo-a-good-stock-to-buy-386777/
*********************************************************

Wed, 18 Nov 2015 15:53:20 GMT ~ China Biologic Products, Inc. Earnings Q3, 2015


read full: http://www.capitalcube.com/blog/index.php/china-biologic-products-inc-earnings-q3-2015/
*********************************************************

Wed, 04 Nov 2015 17:19:05 GMT ~ Edited Transcript of CBPO earnings conference call or presentation 4-Nov-15 12:30pm GMT


read full: http://finance.yahoo.com/news/edited-transcript-cbpo-earnings-conference-171905325.html
*********************************************************

$CBPO charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com



$CBPO company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/CBPO/company-info
Ticker: $CBPO
OTC Market Place: Not Available
CIK code: 0001369868
Company name: China Biologic Products, Inc.
Incorporated In: TX, USA


$CBPO share structure

## source: otcmarkets.com

Market Value: $3,258,445,182 a/o Dec 14, 2015
Shares Outstanding: 26,530,249 a/o Nov 03, 2015
Float: Not Available
Authorized Shares: Not Available
Par Value: 0.0001

$CBPO extra dd links

Company name: China Biologic Products, Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/CBPO/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/CBPO/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=CBPO+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=CBPO+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=CBPO+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/CBPO/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/CBPO/news - http://finance.yahoo.com/q/h?s=CBPO+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/CBPO/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/CBPO/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/CBPO/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/CBPO/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/CBPO/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/CBPO/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/CBPO/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/CBPO/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=CBPO+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/CBPO
DTCC (dtcc.com): http://search2.dtcc.com/?q=China+Biologic+Products%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=China+Biologic+Products%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=China+Biologic+Products%2C+Inc.&x=0&y=0

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/CBPO/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/CBPO
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/CBPO/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/CBPO/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/CBPO/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001369868&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/CBPO/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/CBPO/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/CBPO/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/CBPO/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=CBPO&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=CBPO
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/CBPO/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=CBPO+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=CBPO+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=CBPO
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=CBPO
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=CBPO+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/CBPO/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=CBPO+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/CBPO.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=CBPO
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/CBPO/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/CBPO/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/CBPO/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/CBPO/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/CBPO
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/CBPO
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/CBPO:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=CBPO
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=CBPO



$CBPO DD Notes ~ http://www.ddnotesmaker.com/CBPO

CBPO D

CBPO wtf

$CBPO recent news/filings

bullish
high base breakout

## source: finance.yahoo.com

Fri, 15 May 2015 17:04:13 GMT ~ CHINA BIOLOGIC PRODUCTS, INC. Financials


read full: http://finance.yahoo.com/q/is?s=cbpo
*********************************************************

Wed, 06 May 2015 22:50:17 GMT ~ China Biologic Reports Financial Results for the First Quarter of 2015

[at noodls] - China Biologic Reports Financial Results for the First Quarter of 2015

read full: http://www.noodls.com/view/4AC58FFE952DB03186F32F8E3E0132DD9E42B519
*********************************************************

Wed, 06 May 2015 21:18:36 GMT ~ CHINA BIOLOGIC PRODUCTS, INC. Files SEC form 8-K, Results of Operations and Financial Condition


read full: http://biz.yahoo.com/e/150506/cbpo8-k.html
*********************************************************

Wed, 06 May 2015 21:00:00 GMT ~ China Biologic Reports Financial Results for the First Quarter of 2015

[PR Newswire] - BEIJING, May 6, 2015 /PRNewswire/ -- China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company ...

read full: http://finance.yahoo.com/news/china-biologic-reports-financial-results-210000971.html
*********************************************************

Wed, 06 May 2015 20:38:25 GMT ~ CHINA BIOLOGIC PRODUCTS, INC. Files SEC form 10-Q, Quarterly Report


read full: http://biz.yahoo.com/e/150506/cbpo10-q.html
*********************************************************

$CBPO charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com



$CBPO company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/CBPO/company-info
Ticker: $CBPO
OTC Market Place: Not Available
CIK code: 0001369868
Company name: China Biologic Products, Inc.
Incorporated In: TX, USA

$CBPO share structure

## source: otcmarkets.com

Market Value: $2,524,558,270 a/o May 15, 2015
Shares Outstanding: 24,857,801 a/o May 06, 2015
Float: Not Available
Authorized Shares: Not Available
Par Value: 0.0001

$CBPO extra dd links

Company name: China Biologic Products, Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/CBPO/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/CBPO/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=CBPO+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=CBPO+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=CBPO+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/CBPO/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/CBPO/news - http://finance.yahoo.com/q/h?s=CBPO+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/CBPO/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/CBPO/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/CBPO/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/CBPO/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/CBPO/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/CBPO/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/CBPO/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/CBPO/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=CBPO+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/CBPO
DTCC (dtcc.com): http://search2.dtcc.com/?q=China+Biologic+Products%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=China+Biologic+Products%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=China+Biologic+Products%2C+Inc.&x=0&y=0

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/CBPO/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/CBPO
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/CBPO/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/CBPO/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/CBPO/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001369868&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/CBPO/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/CBPO/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/CBPO/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/CBPO/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=CBPO&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=CBPO
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/CBPO/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=CBPO+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=CBPO+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=CBPO
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=CBPO
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=CBPO+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/CBPO/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=CBPO+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/CBPO.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=CBPO
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/CBPO/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/CBPO/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/CBPO/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/CBPO/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/CBPO
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/CBPO
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/CBPO:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=CBPO
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=CBPO



$CBPO DD Notes ~ http://www.ddnotesmaker.com/CBPO

$CBPO recent news/filings

bullish

## source: finance.yahoo.com

Wed, 08 Apr 2015 21:22:57 GMT ~ Warburg Pincus Reaps $1 Billion Betting on China’s Blood Market


read full: http://www.bloomberg.com/news/articles/2015-04-08/warburg-pincus-reaps-1-billion-betting-on-china-s-blood-market?cmpid=yhoo
*********************************************************

Thu, 12 Mar 2015 17:04:13 GMT ~ CHINA BIOLOGIC PRODUCTS, INC. Financials


read full: http://finance.yahoo.com/q/is?s=cbpo
*********************************************************

Wed, 04 Mar 2015 23:10:02 GMT ~ China Biologic Products posts 4Q profit


read full: http://sg.finance.yahoo.com/news/china-biologic-products-posts-4q-231002324.html
*********************************************************

Wed, 04 Mar 2015 23:10:02 GMT ~ China Biologic Products posts 4Q profit


read full: http://finance.yahoo.com/news/china-biologic-products-posts-4q-231002142.html
*********************************************************

Wed, 04 Mar 2015 22:32:03 GMT ~ China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014

[at noodls] - China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014

read full: http://www.noodls.com/view/C92C635A17122DB37398584D941CCFD725617F41
*********************************************************

$CBPO charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com



$CBPO company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/CBPO/company-info
Ticker: $CBPO
OTC Market Place: Not Available
CIK code: 0001369868
Company name: China Biologic Products, Inc.
Incorporated In: TX, USA

$CBPO share structure

## source: otcmarkets.com

Market Value: $2,402,525,819 a/o Apr 10, 2015
Shares Outstanding: l PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "

6:53AM China Biologic Products comments on proposed Shanghai RAAS transaction; says it 'had no knowledge of the Proposed Shanghai RAAS Transaction prior to the public announcement issued by Shanghai RAAS' (CBPO) 26.50 : Co announced that it has recently learned from a public announcement issued by Shanghai RAAS Blood Products that on May 21, 2013, Ms. Siu Ling Chan, one of the shareholders of the co, and her spouse, Mr. Tung Lam, entered into a stock purchase agreement with Shanghai RAAS. According to the stock purchase agreement, Ms. Chan agreed to sell to Shanghai RAAS an aggregate of 2,657,660 shares of the co's common stock, representing 9.9% of the co's outstanding shares. Shanghai RAAS also stated in its announcement it has an intention to develop strategic business cooperation with the co. China Biologic would like to clarify that the co had no knowledge of the Proposed Shanghai RAAS Transaction prior to the public announcement issued by Shanghai RAAS, nor has the co had any communication or discussion with Shanghai RAAS regarding this transaction. The co considers Shanghai RAAS as one of its direct competitors in China and therefore does not view the Proposed Shanghai RAAS Transaction as a viable transaction. Given the competition between Shanghai RAAS and the co and the differences between the two companies in terms of business strategies and technological capabilities, the co currently has no intention to discuss or explore any business cooperation with Shanghai RAAS.

Short....

Sold out of CBPO.....

9:11AM China Biologic Products receives GMP Certificate for Human Coagulation Factor VIII to start commercial manufacturing this month (CBPO) 9.41 : Taibang earlier received manufacturing approval for FVIII from the SFDA in June 2012. With now both the manufacturing approval and the GMP certificate, Taibang expects start commercial manufacture of FVIII products immediately.

China Biologic Products, Inc. has Analysts' Rating of 1.00, a Return on Assets of 14.44%, and a Net Margin of 21.87%. The short interest was 0.47% as of 08/16/2012. China Biologic Products, Inc., a biopharmaceutical company, through its subsidiaries, engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers Human Albumin for the treatment of shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia. The company also offers Human Hepatitis B Immunoglobulin for the prevention of measles and contagious hepatitis; Human Immunoglobulin and Human Immunoglobulin for Intravenous Injection products for original immunoglobulin deficiency, secondary immunoglobulin deficiency, and auto-immune deficiency diseases; and Thymopolypeptides Injection that is used in the treatment of various original and secondary T-cell deficiency syndromes, auto-immune deficiency diseases, and a range of cell immunity deficiency diseases, as well as assists in the treatment for tumors.
http://seekingalpha.com/article/813382-5-profit-generating-biotech-stocks-that-analysts-love?source=yahoo

8:32AM China Biologic Products Receives SFDA Manufacturing Approval Certificate for Human Coagulation Factor VIII (CBPO) 9.22 : Co announced that its indirectly owned subsidiary, Shandong Taibang Biological Products Co., Ltd. has received a manufacturing approval certificate from the China State Food and Drug Administration for Human Coagulation Factor VIII. With this certificate, the only approval remaining for Taibang's commercial production of FVIII is the SFDA's good manufacturing practice certification of the FVIII production line itself.

8:09AM China Biologic Products names Chairman David Gao to additional post of CEO effective may 10, 2012 (CBPO) 9.23 : Mr. Gao succeeds Mr. Colin (Chao Ming) Zhao, who will continue to serve as the President of the Company. By assuming the CEO position, Mr. Gao has moved from non-executive Chairman to executive Chairman of the Board of Directors. In this connection, Mr. Gao has resigned from his posts in the Company's Audit Committee, Compensation Committee, and Governance and Nominating Committee, effective May 10, 2012. The Company plans to fill the vacancy in the three Committees resulting from Mr. Gao's resignation.

7:25AM On The Wires (WIRES) :China Biologic Products (CBPO) announced that effective Apr 20, 2012, the co's Board of Directors appointed Mr. Zhijun Tong and Ms. Sandy Zhang as two new independent directors of the co

6:03AM China Biologic Products Board elects David Gao as new Chairman (CBPO) 9.28 : Co announced that its Board of Directors has adopted a series of measures to improve the Company's corporate governance, especially to enhance the independence and transparency of the Board. The Board elected David Gao as Chairman of the Board of Directors with effect on March 30, 2012. Gao succeeds Siu Ling Chan who served for more than five years as China Biologic's Chairwoman. Chan will remain as a Director on the Board.

~ Monday! $CBPO ~ Earnings posted, pending or coming soon! In Charts and Links Below!

~ $CBPO ~ Earnings expected on Monday *
Want more like this? Search Keyword: MACMONEY >>> http://tinyurl.com/MACMONEY <<<
One or more of many earnings sites has alerted this security has or will be posting earnings on or around the day of this message.








http://stockcharts.com/h-sc/ui?s=CBPO&p=D&b=3&g=0&id=p88783918276&a=237480049




http://stockcharts.com/h-sc/ui?s=CBPO&p=W&b=3&g=0&id=p54550695994



~ Google Finance: http://www.google.com/finance?q=CBPO
~ Google Fin Options: hhttp://www.google.com/finance/option_chain?q=CBPO#
~ Yahoo! Finance ~ Stats: http://finance.yahoo.com/q/ks?s=CBPO+Key+Statistics
~ Yahoo! Finance ~ Profile: http://finance.yahoo.com/q/pr?s=CBPO
Finviz: http://finviz.com/quote.ashx?t=CBPO
~ BusyStock: http://busystock.com/i.php?s=CBPO&v=2


<<<<<< http://www.earningswhispers.com/stocks.asp?symbol=CBPO >>>>>>



http://investorshub.advfn.com/boards/post_prvt.aspx?user=251916

*If the earnings date is in error please ignore error. I do my best.

6:24AM On The Wires (WIRES) China Biologic Products (CBPO) announced that its indirectly owned subsidiary, Shandong Taibang Biological Products, recently received approval from the China State Food and Drug Administration to begin clinical trials for its human fibrinogen to be used to treat congenital fibrinogen deficiency and acquired fibrinogen deficiency.

http://www.secform4.com/insider-trading/1369868.htm

http://www.secform4.com/insider-trading/1369868.htm

http://www.thestreet.com/_yahoo/story/11337421/1/insiders-trading-vmw-exls-cbpo-mgln.html?cm_ven=YAHOO&cm_cat=FREE&cm_ite=NA

3 Oversold Biotech Stocks Undervalued By Levered Free Cash Flow

2. China Biologic Products, Inc. (CBPO): Engages in the research, development, manufacturing, and sale of plasma-based pharmaceutical products. Market cap of $173.99M. RSI(14) at 37.14. Levered free cash flow/enterprise value at 15.16% (levered free cash flow at $17.88M and enterprise value at $117.96M). The stock is a short squeeze candidate, with a short float at 6.28% (equivalent to 44.65 days of average volume). The stock is currently stuck in a downtrend, trading 11.78% below its SMA20, 20.2% below its SMA50, and 47.87% below its SMA200. It's been a rough couple of days for the stock, losing 11.1% over the last week.

http://seekingalpha.com/article/296333-3-oversold-biotech-stocks-undervalued-by-levered-free-cash-flow?source=yahoo

9:29AM China Biologic Products 2 plasma collection stations in Guizhou Province have been inspected and relicensed, 4 other stations in disallowed counties closed on August 1, 2011 (CBPO) 9.40 : Co announced that 2 of its plasma collection stations, in Pu Ding and Huang Ping counties in the Guizhou Province, passed inspection and have been relicensed today for operation for 2 years, and will continue to operate. The licenses for these 4 other plasma collection stations in Dan Zhai, Wei Ning, San Sui, and Na Yong counties have expired on July 31, 2011 and have not been inspected and relicensed. The co expects these 4 stations will cease operations until at least August 1, 2013.

China Biologic Products 2 plasma collection stations in Guizhou Province have been inspected and relicensed, 4 other stations in disallowed counties closed on August 1, 2011 (CBPO) 9.40 : Co announced that 2 of its plasma collection stations, in Pu Ding and Huang Ping counties in the Guizhou Province, passed inspection and have been relicensed today for operation for 2 years, and will continue to operate. The licenses for these 4 other plasma collection stations in Dan Zhai, Wei Ning, San Sui, and Na Yong counties have expired on July 31, 2011 and have not been inspected and relicensed. The co expects these 4 stations will cease operations until at least August 1, 2013.

China Biologic Evaluating Possible Effects from a Revised Provincial Plan on Plasma Collection Stations in Guizhou Province

Press Release Source: China Biologic Products, Inc. On Friday July 15, 2011, 8:30 am EDT

TAI'AN, China, July 15, 2011 /PRNewswire-Asia-FirstCall/ -- China Biologic Products, Inc. (NASDAQ:CBPO - News) ("China Biologic," or the "Company"), a leading plasma-based biopharmaceutical company in China, today announced that the Guizhou Provincial Health Department has issued the revised "Plan for Guizhou Provincial Blood Collection Institutional Setting (2011-2014)" (the "Revised Plan"). The Revised Plan reduces the number of counties that are permitted to set up plasma collection stations from the originally proposed 10 counties to 4 counties.

The Revised Plan, in the relevant part, states that "in accordance with the demographic distribution, economic development condition, disease prevalence, and actual situation of plasma supply for the manufacturing of blood-based products, plasma collection stations will be set up in 4 counties, including Kai Yang, Du Shan, Pu Ding, Huang Ping, etc."

Currently, there are 18 plasma collection stations, in 18 separate counties, operating in Guizhou Province. China Biologic's 54% indirectly owned subsidiary, Guizhou Taibang Biological Technologies Co., Ltd., currently has 6 active plasma collection stations in the Guizhou Province. Among the 6 active plasma collection stations, 2 are located in the counties included in the Revised Plan (Pu Ding and Huang Ping) and are currently expected not to be affected directly by the Revised Plan.

Based on the Company's preliminary understanding of the Revised Plan, subject to further clarifications from Guizhou Provincial government regarding the implementation of the Revised Plan, the Company currently anticipates the licenses of its 4 other plasma collection stations in Dan Zhai, Wei Ning, San Sui, and Na Yong counties may not be renewed (until at least 2014) after their respective plasma collection permits expire at the end of July 2011.

The Company's 4 stations in Dan Zhai, Wei Ning, San Sui, and Na Yong counties together accounted for approximately 34.1% of China Biologic's total plasma collection by volume in 2010. In addition, 1 inactive plasma collection station that the Company purchased from the government is unlikely to be licensed as planned, because it is in Zhengyuan County, a location not included in the Revised Plan.

The 2 active plasma stations in the counties included in the Revised Plan that are expected to continue operating are scheduled for relicensing before the end of July. The relicensing will require inspection of the plasma collection stations by provincial and other government officials. While the Company believes it meets or exceeds all inspection requirements at those stations, it is not yet clear what influence on the inspections the Revised Plan may have, if any.

The Company is currently evaluating the effect of the Revised Plan and the anticipated closing of the 4 active plasma collection stations including, among other items, the potential reduction in China Biologic's previously issued financial guidance for the year 2011, potential reduction in its business operations and financial performance in current and future periods, potential assets impairments associated with these plasma collection stations and the 1 inactive station, and other possible effects.

In a bid to mitigate the reductions from the anticipated closing of the 4 plasma collection stations in Guizhou, the Company is exploring alternative solutions and opportunities, but no assurance can be given that it will be successful in doing so. Among all of the Company's efforts, the Company is (1) requesting that the Guizhou Provincial government to reconsider the implementation of the Revised Plan, (2) contemplating new regions to apply for establishing new plasma stations, (3) minimizing the writing off of already collected plasma within the required 90-day quarantine period that potentially may be affected by the Revised Plan, and (4) creating the contingency plan for moving assets and paying severance to employees related to the 4 plasma collection stations affected by the Revised Plan, if the anticipated closures happen.

China Biologic Products (CBPO) fell 7% after the Guizhou Provincial Health Department issued the revised "Plan for Guizhou Provincial Blood Collection Institutional Setting (2011-14).” The revised plan reduces the number of counties that are permitted to set up plasma collection stations from the originally proposed 10 counties to four counties. The revised plan, in the relevant part, states that

in accordance with the demographic distribution, economic development condition, disease prevalence, and actual situation of plasma supply for the manufacturing of blood-based products, plasma collection stations will be set up in four counties, including Kai Yang, Du Shan, Pu Ding, Huang Ping, etc.

Based on the company's preliminary understanding of the revised plan, subject to further clarifications from Guizhou Provincial government regarding the implementation of the plan, the company currently anticipates the licenses of its four other plasma collection stations in Dan Zhai, Wei Ning, San Sui, and Na Yong counties may not be renewed (until at least 2014) after their respective plasma collection permits expire at the end of July.

http://seekingalpha.com/article/279926-5-stocks-lower-on-friday?source=yahoo

3. China Biologic Products, Inc. (CBPO): Biotechnology Industry. Market cap of $224.26M. MRQ total debt to assets at 0.04. TTM net profit margin at 31.96% vs. prior-year TTM net profit margin at 21.90%. The stock is a short squeeze candidate, with a short float at 8.13% (equivalent to 19.55 days of average volume).It's been a rough couple of days for the stock, losing 14.96% over the last week.

http://seekingalpha.com/article/280210-7-low-debt-biotech-stocks-with-improving-profitability?source=yahoo

8:56AM On The Wires (WIRES) :

China Biologic Products (CBPO) announced that it has received the permit from the Shandong Province Health Department for the newly built plasma collection station in Ningyang County, Shandong Province, and expects to begin commercial plasma collection at the Ningyang station on July 12, 2011.

I see no evidence of shorting on the chart...yet. China sector has been bombarded with negative media lately. The low float plus low dollar volume of the exchanges makes it perfect breeding ground for shorts. Possible panic of Mutual Funds seeing dollar volume shifting from domestic US stocks to China domestic traded stocks. Mutual Funds want to have good reporting 4Q's...thus negative media blasts. What did they dig up..a stolen car conviction as a teenager or child support evasion?

hey, whats the outcome with the allegation of the CEO as a former criminal?

CBPO 6 month chart
Institutional ownership
http://www.dailyfinance.com/company/china-biologic-products-inc/cbpo/nas/institutional-ownership
CBPO New Institution Trading Report
http://206.222.29.162/institution/subject.jsp?subject=0001369868&company=CBPO
Fundies
http://finviz.com/quote.ashx?t=cbpo&ty=c&ta=1&p=d
Rames list: China Valuation Screen - Main Exchanges
http://fixyou.co.uk/valuation_main.php
White_Tiger
http://geoinvesting.com/companies/cbpo_china_biologic/research
China+1 screen
http://www.chinaplus1.com/content/16282
Filings
http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001369868&owner=include&count=40
URL http://www.stockcharts.com/h-sc/ui?s=cbpo&p=d&yr=0&mn=6&dy=0&id=p43580791654&a=205120576

CBPO chart expanded from September 2009. This post is on my chart thread. Will work on the float annotations tonight. I love resurrecting all this old stuff!
URL http://www.stockcharts.com/h-sc/ui?s=cbpo&p=d&yr=1&mn=6&dy=15&id=p07519112849&a=205092356

8:01AM China Biologic products subsidiary awarded center of excellence designation in China (CBPO) 10.99 : Co announced that its indirect majority-owned subsidiary, Shandong Taibang Biological Products Co. Ltd. ("Shandong Taibang"), has been recognized as one of Shandong's National Centers of Excellence for New Drug and Technology Development ("SNC") by the Department of Science and Technology of Shandong Province (the "DSTSP"). The DSTSP created the SNC designation to help implement and advance major drug development strategies proposed by China's Ministry of Science and Technology of PRC. SNC companies are chosen based on a number of criterion including: annual sales exceeding 500 mln RMB (or ~$73 mln) or ownership of independent intellectual property rights for new drugs; Good Manufacturing Practices (GMP) certified; a track record of strong pharmaceutical R&D capabilities and highly qualified R&D team; and evidence of continued commitment to and advances in new drug development.

Brean Murray maintains a 'Buy' on China Biologic Products (CBPO); Triple-Digit Growth Reflects Strong Business Fundamentals

Brean Murray maintains a 'Buy' on China Biologic Products (Nasdaq: CBPO), raises price target from $15 to $19

I have posted comments about the "criminal" former CEO at seekingalpha

http://seekingalpha.com/instablog/500579-worthless-pennies/45557-china-biologic-there-will-be-blood#comment_update_link

The biggest problem is that according to SEC filing

http://www.sec.gov/Archives/edgar/data/1369868/000093041307007153/c46541_sb2.htm

Tung, Lam has been the Chief Executive Officer of our operating subsidiary, Shandong Taibang, since October 2003, and is responsible for the entire operation. Mr. Lam served, from March 2001 to August 2003, as the vice president of the Fujian Province Fei Yue Group, where he was in charge of management investment. Mr. Lam graduated from Fuzhou University majoring in business administration in 1983. He also received a EMBA degree from People’s University of China in 2006

If My Lam Tung graduated from Fuzhou University, this is completely different from Mr. Lin Zipin's Page 3 resume, which is totally military based experience.

I am glad to see its strengthening here as well. There is only one amended S1A filed today. I don't see it as the mover.

But I won't put too much into one day. It is very tricky to time market in short period, let alone individual stock. As long as we focus on fundamental, we should be ok after this roller coaster... though I am getting a little dizzy now.

CBPO Up-Nicely today. Have you heard any News? CBPO is one of the few stocks in my China portfolio that are up.

In regard to the overall market:
Once this selloff has run its course, I'm looking to add to some that I've either pared back or only nibbled on. However in my experience, it doesn't pay to stand in front of a freight train. Hence, I'm not quite yet ready to pounce. Someone else can catch the bottom. I'll just wait to hopefully allow the bottom to reveal itself. In the meantime, I'm sharing in the pain.

Patience is a virtue for this stock. Its cycle is a little longer than couple days. Currently in down cycle.

Can anyone tell me what's going on with CBPO since 11 Jan? Are we going up to 14 anytime soon or down further? Thanks!

CBPO has been doing great! Since Dec. uplisting, it finally appeared in IBD rating. At the beginning, it was incomplete and hover around 60-70. This morning I checked again, it is already #1 in its group which includes power house like Amgen. It should be cracking IBD#100 soon in this rate.

Its TTM EPS (non-gaap) is 1.01 and apply only 30% growth for 2010. It will be only 1.31. Assigning PE=15 as it is much safer play now in big board and potential increase from indexes and instituional buyers. The target is 19.7, which should leave about 50% PPS growth in 2010. So holding for LTCG for 2010 seems to be safe bet.

CBPO moving up.
Everybody seems to moving into the Chinese stocks today.
I guess people are finally realizing where the growth is.

China treats severe swine flu patients with plasma harvested from recovered, vaccinated people

http://www.google.com/hostednews/canadianpress/article/ALeqM5hqY9yvFjHpmFGCz-O1e2oOHSl_ZQ

rich

It just plays elevator music..its at CGR IR

Like the video. I think this one is bound to go up
after it gets a little more attention from the investing world.

Has no sound!! ??

I agree...

According to Q3 filing and CC, the lawsuit is shifted back TaiAn from Wuhan. The threat of the lawsuit is diminishing. With this even more so in rear view mirror, moving to "big board ASAP " according to Kritin. I think the two major hurdles are disappearing for CBPO to go over $10.

" on September 25, 2009, the Higher People’s Court of Hubei overruled the Wuhan Intermediate Court’s acceptance of jurisdiction over the case and ruled that the Tai’an Intermediate Court in Shandong Province, where the Company is located, had the proper jurisdiction over the parties’ dispute. As a result, the attached 66% of the equity of Shandong Taibang were released. The court ruled that while the plaintiffs had the right to bring a lawsuit for the validity of the share transfer agreement because they did not attend the previous arbitration hearing and never reached an arbitration agreement regarding their dispute, the Tai’an Intermediate Court has the proper jurisdiction over the dispute pursuant to the prior agreement of the parties. Although the plaintiffs may decide bring their suit to Tai’an, Management believes that the possibility of the plaintiffs prevailing in Tai’an is slim in light of the historical Tai’an proceedings in connection with the dispute: a Tai’an arbitration panel has already confirmed that the share transfer agreements are effective, including the share transfer agreement between the plaintiffs and the Company, and the Tai’an Intermediate Court has already confirmed the legal force of the arbitration award. Failure to resolve these disputes in our favor may adversely affect our business and operations.

Thank you.Hope all is well ,your a gentleman.

The older 2006 warrants were called in, but there were some new warrants issued as part of the 2009 convert deal. I can't claim to know what the charges will be, but in general, as the stock price rises in any quarter, the cost of the non-cash derivative charges increases.

I expect that there will be charges for the converts as well as the warrants. I would also recommend backing them out from the income statement, as they have no impact on cash flow are merely an accounting convention. Hopefully this will be clearly spelled out in the PR to come.

abh3vt do you have the non-cash charges figured out for this qtr??? Old warrants were called but new conv preferred was issued..thanks for your help

I was going to respond more fully to you until I saw this (which indicates to me that you have made up your mind already):

I move on and am done with this.

I'm not sure there are any explanations or reasoned arguments that will change your outlook. All I can say is that the company has an equally strong position that is opposite to Mr. Du's regarding the basis of the lawsuit. I wish that it could have been settled long ago, and the longer it hangs around will give posters like you stuff to speculate about.

I think you are way off base in your speculation about the worst case scenario for US shareholders. I would also refer you to recent SEC filings that show several large and sophisticated investors have made substantial investments in this company this year with full knowledge of this (and other) lawsuits that the company has been facing.

Since you seem to enjoy doing this type of DD, why don't you report back to us on the identity of the institutional investors who have taken a position in CBPO? Perhaps give a more nuanced view of the investment opportunity here rather than slam the company on two public bulletin boards?